Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shared neoantigen vaccine 1
- Development stage
- Preclinical
- Lead developer
- NeoCura
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Shared neoantigen vaccine 1 is an investigational mRNA-based cancer vaccine being developed by NeoCura Bio-Medical Technology. Unlike personalized neoantigen vaccines that are custom-made for individual patients, this therapeutic belongs to the NeoCura Ag-COM product line, which utilizes shared or "public" neoantigen sequences. These sequences represent common oncogenic mutations found across multiple patients with various tumor types, allowing for a standardized, off-the-shelf treatment approach. The vaccine's mechanism of action involves using mRNA technology to encode these shared neoantigens, which, upon administration, stimulate the immune system to activate tumor-specific T cells and induce a robust anti-tumor response. The drug is currently in the IND-enabling phase of development for the treatment of multiple cancer types.
- Other names
- NeoCura Ag-COMNeoCura Agshared neoantigen vaccine
02
Targets
NeoAg-HLA-I (Tumor neoantigen-HLA class I complex)
Beyond the preview
Go deeper on Shared neoantigen vaccine 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shared neoantigen vaccine 1.